cyrilzakka/clinical-trials huggingface dataset:
Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease

The purpose of this observational study is to examine patterns of treatment care for patients with Alzheimer's disease (AD) in a real-world arena and to examine the association with different outcomes for patients and informal caregivers.

This is a 2-year, multicenter, prospective (look forward using periodic observations collected predominantly following patient enrollment), longitudinal (it is a co relational research study that involves repeated observations of the same variables over long periods of time), and observational study. The objective of this study is to examine the patients with mild and moderate AD who are currently being treated with different treatment care methods in real-world settings. Doctors will not be provided medication or asked to treat their patients with any particular treatment. The effect of the different management strategies on cognition, activities of daily living, and behavior of the patients will be evaluated, and data on the informal caregiver burden will be assessed. Data on the utilization of health and social care services by the patient and the primary informal caregiver, including admission of the patient to an assisted living facility or nursing home will be assessed. The doctor's assessment of clinical global impression and adverse events will also be documented. Data will be collected from the doctors at baseline and at 6, 12, and 24 months, and from the caregivers at baseline and 6, 12, 18, and 24 months. The medication dosage and administration is based upon the doctors' prescription, individualized for the patient and not dictated by the protocol.

Eligibility Criteria:
Inclusion Criteria:

* Have a physician-based diagnosis of mild to moderate Alzheimer's disease (Mini-Mental State Examination \[MMSE\] score between 10-24)
* Must be living at home or in a facility for the elderly (eg, assisted living), who live with or have frequent visits from a friend or relative (caregiver) or with a behavioral symptom (eg, as agitation or wandering)
* Have no plan to change the current treatment plan for at least 90 days

Exclusion Criteria:

* Have been using an acetylcholinesterase inhibitor or memantine currently but have used one in the past 30 days
* Must be residing in or planning to move to a nursing home within the next 90 days or patients participating in another clinical trial
Movement Disorder Survey in East China

Movement disorder involve recurring or constant muscle contractions causing squeezing or twisting movement, such as hemifacial spasm, blepharospasm, cervical dystonias etc. The most common focal dystonia was cervical dystonia in western countries according to previous studies, which is different from China in Chinese neurologists' opinion. And there is no such survey. So the investigators are conducting a movement disorder survey in east China to confirm it.


Eligibility Criteria:
Inclusion Criteria:

* Patients seeking treatment in movement disorder clinics(include naive or may have previously been to clinics)

Exclusion Criteria:

* Patients who have received this movement disorder survey
A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity

The purpose of the investigators study is to determine the relationship between the length of the eye and the rate of change in eye length at each visit with progression of retinopathy of prematurity.


Eligibility Criteria:
Inclusion Criteria:

* neonates being screened for retinopathy of prematurity

Exclusion Criteria:

* medically unstable neonates
Novel Approach for Embryo Transfer Medium by Adding Cytokine to Hyaluronan Enriched Embryo Transfer Medium (Embryo Glue)

It was proven that the Cytokine granulocyte-Macrophage clony stimulating factor had been found naturally in reproductive tract so our target is to test its effect if added to embryo transfer medium.

The IVF embryo transfer media design and upgrade underwent many ideas during the last 3 decades, we suppose that adding Cytokine GM-CSF as an endometrial modifier to already proven successful medium hyaluronan enriched medium to test the efficacy ipon pregnancy and implantation rate in vitro so we decide to design a trial to compare the clinical outcome by sibling embryo to be transferred into 2 groups and the same culture condition but with one arm with Cytokine and the other is traditional one and closely monitor the outcome within the 2 arms and record the results.

Eligibility Criteria:
Inclusion Criteria:

* all patients

Exclusion Criteria:

* above 40 years old
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind

The purpose of this project is to study brain imaging of a substance called tau, which is found in brains of persons with Alzheimer's disease, using the Tau binder, 18F-THK-5351, for live imaging of tau in the brain. The main goal of this proposal is to study whether diabetes status (type 2 diabetes \[referred to as diabetes\] and pre-diabetes, compared with normal glucose tolerance \[NGT\]), is associated with increased tau accumulation in the brain, one of the culprits of Alzheimer's disease, in a community-based group of middle aged Caribbean-Hispanics with a mean age of 63 years. The investigators propose to conduct tau positron emission tomography (PET) imaging in 30 middle aged Hispanics.

The burden of late onset Alzheimer's dementia (LOAD) and its antecedents is increasing without known prevention or cure, and diabetes seems to be one of the strongest risk factors. The predominating causal model in Alzheimer's disease (AD) research is based on the amyloid hypothesis, which posits that amyloid (A) deposition in the brain causes synaptic dysfunction resulting in early memory deficits and progression to mild cognitive impairment (MCI) and dementia. Tau has also gained increasing interest as an AD pathology feature, biomarker, and treatment target.

There are no known curative or preventive measures for LOAD. One of the strongest potential LOAD risk factors is type 2 diabetes, an abnormal elevation of blood glucose associated with microvascular and macrovascular complications including cerebrovascular disease. Many studies have reported an association of diabetes with dementia, including LOAD and vascular dementia (VD). Most studies have found that diabetes is associated with an increased risk of both LOAD and VD, with a stronger association for VD compared with LOAD. Thus, this study focuses on the relation of diabetes, pre-diabetes, and elevated glucose, with AD.

Eligibility Criteria:
Inclusion Criteria:

* All persons who have undergone magnetic resonance imaging (MRI) and amyloid PET already, or those who prospectively are deemed eligible for the parent study covered under protocol AAAQ2950, will be approached for participation.

Exclusion Criteria:

* Person who are not participating in the MRI and amyloid PET under protocol AAAQ2950
Adapted Lifestyle-integrated Functional Exercise Program for Medically Underserved Older Adults

This study will test the feasibility of a study design for the Adapted Lifestyle-integrated Functional Exercise (LiFE) program for medically underserved older adults and to explore factors related to implementation. A feasibility trial will be conducted with a total of 16 participants. The control group will receive flexibility exercise program as attention control.

This study will test the feasibility the Adapted Lifestyle-integrated Functional Exercise (LiFE) program among medically underserved older adults. Sixteen medically underserved older adults will be recruited in the study and randomized to Adapted LiFE or attention control group (flexibility exercise program). Process outcomes and preliminary outcomes will be collected to determine feasibility and preliminary efficacy. Process outcomes such as reach, acceptance, adherence, fidelity, and safety will also be collected throughout the study. Preliminary efficacy outcomes include habit formation, balance, muscle strength will be collected at baseline and at immediately after intervention is completed.

Eligibility Criteria:
Inclusion Criteria:

* (1) age 70 or older;
* (2) live independently;
* (3) live in a medically underserved/health professional shortage area;
* (4) self-report two falls or one injurious fall.

Exclusion Criteria:

* (1) Short Blessed Test score ≥8, indicating cognitive impairment consistent with dementia;
* (2) inability to stand independently with a walking device;
* (3) having a serious health condition with a physician's order where exercise is contraindicated.
Individual and Family Therapy for Children With Anxiety Disorders

The purpose of this study is to compare three treatments to determine which is most effective in reducing anxiety in children.

Children and their parents will complete a comprehensive diagnostic assessment to determine eligibility. The assessment will include an individual diagnostic interview with the child, interviews with the parents, and written observations of the child from family members and teachers. Participants will then be randomly assigned to receive individual cognitive behavioral therapy (ICBT), family CBT (FCBT), or education/support/attention (ESA) for 5 months. Children in the ICBT group will meet individually with a therapist. In the FCBT and ESA treatment groups, children and their parents will meet weekly with a therapist.

At the end of treatment and 1 year following treatment completion, families will complete another assessment to determine the effectiveness of each treatment at reducing short- and long-term anxiety symptoms in their children.

Eligibility Criteria:
Inclusion Criteria:

* Child with DSM-IV criteria for separation anxiety disorder, social phobia, or generalized anxiety disorder

Exclusion Criteria for Child Participants:

* IQ less than 80
* Current use of anti-anxiety or antidepressant medications
* Psychotic symptoms
* Child and/or parent is non-English speaking
Simulation-Based Central Venous Line Maintenance Bundle Education

Catheter associated blood stream infections (CA-BSI) remain a source of significant morbidity and mortality in adult and pediatric critical care units. While it has been established that CVL maintenance bundles are pivotal to achieving and maintaining low CA-BSI rates, training and retention of proper bundle compliance remains a challenge.

The investigators prospectively compared this simulation-based program to a standard educational approach.

The investigators hypothesized that implementation of bedside simulation-based training of CVL dressing changes by registered nurses would improve CVL maintenance bundle compliance.

The 2006 NACHRI Quality Transformation Effort demonstrated that additional reduction in pediatric catheter associated blood stream infection (CA-BSI) rates could be achieved through improving compliance with maintenance bundle care for central lines. The investigators objective was to improve maintenance bundle compliance rates and nursing competency surrounding central venous line (CVL) care in their pediatric intensive care unit (PICU).

A multidisciplinary team developed a bedside simulation-based training program to improve compliance with standard PICU CVL maintenance bundle. The investigators then performed a randomized comparison study comparing a standard CVL bundle education process for bedside PICU nurses in a control group (CG) to an intervention group (IG) receiving bedside training to simulate a CVL dressing change and maintenance bundle followed by intermittent educational refresh. Groups were assessed for compliance with prescribed components of the CVL bundle maintenance (CVL score).

CVL scores will be compared between groups

Eligibility Criteria:
Inclusion Criteria:

* Any nurse assigned to the PICU on a regular basis was eligible to participate in the study, including full-time, part-time, and occasional (prn) PICU nursing staff, as well as central staffing office (ICU float nurses) and traveler nurses contracted to the PICU for a minimum of 12 weeks

Exclusion Criteria:

* Nurses floating from other units, agency nursing personnel, or traveler nurse contract of \< 12 week period were excluded. Nurses on orientation were excluded until completion of introductory 6-month probation period
Optical Coherence Tomography-based Positioning for Macular Hole Surgery

The efficacy of macular hole (MH) surgery with the halting of prone positioning by monitoring the MH closure in the swept source optical coherence tomographic (SS-OCT) images was compared with the surgery by the surgeon's decision. The macular hole closure and visual outcome were compared.

The efficacy of macular hole (MH) surgery with the halting of prone positioning by monitoring the MH closure in the swept source optical coherence tomographic (SS-OCT) images was compared with the surgery by the surgeon's decision. All eyes were treated by pars plana vitrectomy, internal limiting membrane peeling, and gas tamponade. MH closure was defined as a connection of the edges of the sensory retina in the SS-OCT images.The macular hole closure and visual outcome were compared.

Eligibility Criteria:
Inclusion Criteria:

* The patients were followed more than 2 months.

Exclusion Criteria:

* Eye with axial length more than 26.0 mm
Positron Emission Tomography in Detecting Testicle Cancer

RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to detect the extent of cancer and allow doctors to plan more effective treatment for patients who have testicle cancer.

PURPOSE: Diagnostic trial to study the effectiveness of positron emission tomography using fludeoxyglucose F 18 in predicting relapse in patients who have stage I germ cell tumor of the testicle.

OBJECTIVES:

* Assess the ability of fludeoxyglucose F 18 positron emission tomography to predict relapse requiring adjuvant chemotherapy in patients with high-risk stage I non-seminomatous or mixed seminoma/non-seminomatous germ cell tumor of the testis who are on current management protocols.

OUTLINE: This is a multicenter study.

Patients receive fludeoxyglucose F 18 (FDG) IV followed 1 hour later by positron emission tomography (PET) imaging. Patients with metastatic disease identified by FDG PET imaging may receive adjuvant chemotherapy according to the standard clinical practice at each participating center. Patients with no metastatic disease identified by FDG PET imaging are considered for entry into the MRC-TE08 trial (randomized trial of 2 CT scan frequencies in the surveillance of stage I teratoma) or are followed according to the standard surveillance schedule.

Patients with metastatic disease are followed every 6 months. Patients with no metastatic disease are followed monthly for 1 year, every 2 months for 1 year, every 3 months for 1 year, and then every 4-6 months thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: Approximately 135 patients will be accrued for this study within 2-3 years.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically confirmed non-seminomatous or mixed seminoma/non-seminomatous germ cell tumor of the testis with evidence of vascular (lymphatic or venous) invasion in primary specimen
* Clinical stage I on the basis of clinical examination, chest x-ray, and CT scan of the chest, abdomen, and pelvis
* Negative post-orchidectomy tumor markers (alpha-fetoprotein and beta human chorionic gonadotropin)
* High-risk disease

PATIENT CHARACTERISTICS:

Age

* Any age

Performance status

* Not specified

Life expectancy

* Not specified

Hematopoietic

* Not specified

Hepatic

* Not specified

Renal

* Not specified

Other

* No evidence of active inflammatory or infective diseases
* No other disease or prior malignancy that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* Not specified

Endocrine therapy

* Not specified

Radiotherapy

* Not specified

Surgery

* See Disease Characteristics
* No more than 8 weeks since prior orchidectomy

Other

* No prior positron emission tomography scans
Bioequivalence Study of Ciprofloxacin in Healthy Adult Subjects Under Fasting Condition

To evaluate and compare the relative plasma bioavailability and therefore the bioequivalence of two different immediate release products each containing Ciprofloxacin 750 mg, after administering a single oral dose, to healthy adult subjects under fasting conditions.

Enrolled subjects were randomized in a two-phase, two-sequence, cross-over design to receive a single dose of the test product (T) or the reference product (R) at each phase, under fasting conditions, with a wash-out period of 7 days.

Ciprofloxacin plasma concentrations were determined using a validated LC-MS-MS method, followed by Pharmacokinetics, and statistical analysis using Phoenix WinNonlin® software to determine the average bioequivalence.

Eligibility Criteria:
Inclusion Criteria:

* Written informed consent is obtained for study.
* Age 18 - 55 years,
* Body mass index between 18.5 and 30 kg/m2
* Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination.
* Vital signs without significant deviations.
* All laboratory screening results are within the normal range or clinically non-significant

Exclusion Criteria:

* History or presence of any disorder or condition that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the investigator.
* History of any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, allergic, dermatologic, hematologic, neurologic, or psychiatric disease, or cancer.
* Any confirmed significant allergic reactions against any drug or multiple allergies.
* Clinically significant illness 28 days before study phase I.
* Alcohol or any solvent intake.
* Regular use of medication.
* Positive urine screening of drugs of abuse.
* Use of any systemic medications (prescription medications, OTC products, supplements, or herbal preparations) for 14 days prior to dosing and during the study.
* History or presence of significant smoking (more than one pack per day of cigarettes) or refusal to abstain from smoking for 48 hours before dosing until checkout.
* Blood donation within the past 60 days.
* Participation in another bioequivalence study within 60 days prior to the start of phase I of the study
Prevalence and Risk Factors for Postoperative Delirium 48 Hours After Surgery

To determine the overall prevalence of postoperative delirium (POI) and its association with different risk factors in order to establish prevention plans to reduce its incidence and/or duration in Spanish hospitals.

To this end, patients over 18 years of age who underwent urgent and scheduled surgery requiring hospital admission under any type of anaesthesia during two specific days will be recruited and pre-, intra- and postoperative data will be collected.


Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 years of age undergoing urgent and scheduled surgery requiring hospital admission, under any type of anaesthesia.

Exclusion Criteria:

* Presence of pre-surgical delirium.
* Outpatient surgery.
Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma

This study on biological samples of patients affected by neuroblastoma and Ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.


Eligibility Criteria:
Inclusion Criteria:

* diagnosis of Ewing sarcoma or neuroblastoma

Exclusion Criteria:

* sieropositivity
Self-Efficacy and Medication Adherence in Patients With Coronary Artery Disease: A Descriptive Study

This descriptive study aims to examine the relationship between self-efficacy and medication adherence in individuals with coronary artery disease (CAD). The study will be conducted between March and October 2025 at Adıyaman University Training and Research Hospital with a planned sample size of 135 participants. Data will be collected using a Descriptive Information Form, the Self-Efficacy for Managing Chronic Disease Scale, and the Medication Adherence Report Scale (MARS).

Coronary artery disease (CAD) remains one of the leading causes of death worldwide. Managing CAD requires long-term treatment adherence and lifestyle changes. Self-efficacy, which reflects an individual's belief in their ability to perform specific health behaviors, plays a key role in disease management. In CAD patients, high levels of self-efficacy have been associated with better treatment adherence, improved symptom management, and successful adoption of healthy behaviors.

This descriptive study is designed to investigate the relationship between self-efficacy and medication adherence in individuals diagnosed with CAD. The study will be carried out at Adıyaman University Training and Research Hospital between March and October 2025. The target population includes patients who have been diagnosed with CAD (e.g., angina pectoris, myocardial infarction) for at least one year and meet the inclusion criteria. Based on a power analysis using G\*Power software (effect size f² = 0.15, α = 0.05, power = 0.90), the required sample size is calculated as 112. However, accounting for possible data loss or participant dropout, the final sample size is set at 135.

Data collection tools include:

Descriptive Information Form to assess demographic and clinical characteristics,

The 6-Item Self-Efficacy for Managing Chronic Disease Scale, validated in Turkish by İncirkuş and Özkan Nahcivan (Cronbach's alpha = 0.90),

Medication Adherence Report Scale (MARS), adapted to Turkish by Temeloğlu Şen et al. (Cronbach's alpha = 0.78).

The findings are expected to contribute to the literature and guide healthcare professionals, particularly nurses, in planning educational and counseling services to improve self-efficacy and medication adherence among CAD patients.

Eligibility Criteria:
Inclusion Criteria:

* Being 18 years of age or older

Having been diagnosed with Coronary Artery Disease (angina pectoris, unstable angina, myocardial infarction) at least 1 year ago

Being followed

Being able to communicate in Turkish

Voluntarily agreeing to participate in the study

Having no diagnosed mental disorder

Exclusion Criteria:

* Having a primary diagnosis other than Coronary Artery Disease

Being unable to complete the questionnaires due to mental health problems

Providing incomplete data or withdrawing from the study